Russia infection control market is projected to grow at a CAGR of 6.81% over the forecast period 2019 to 2025. There is lack of awareness and presence of poor hygiene practices in most of the Eurasian countries, due to the absence of using evidence-based approaches to medicine and public health, which has increased the number of nosocomial infections, or the infection acquired in the hospital. This has resulted in the expansion of training centers and research facilities in order to combat, which is a burdening situation, due to which AIHA developed an infection control, program which was a region-wide and cross-partnership program. The program was in collaboration with Harvard Medical International, Hospital Infection Prevention and Quality Assessment (INQUAL), among some other institutions and healthcare bodies in the year 1997, and continuous improvements were made in the years 2001 up to 2004. Thus, the presence of this action is a contributing factor tor to the market growth.
There is a growing awareness among the population in regards to avoiding the spread of infections by following proper disinfection and infection control methods, which is leading them to demand more advanced and better medical treatment conditions and facilities from the healthcare workers, thus urging them to adopt these practices. This is leading to an increased demand for infection control technologies, products and solutions, and causing a surge in the market growth.
Furthermore, product offerings are one of the initiatives that are being taken by the market players, so that they are able to maximize their profits, gain a competitive edge over their rivals, and fulfill the ever-rising demand of enhanced infection control products and provide a boost to the market growth. For instance, BD, one of the leading medical technology companies that are dealing in the manufacture and sale of medical devices, instrument systems, and other chemical reagents, and is based in America, offers a range of products under their product portfolio. It offers a product called the ChloraPrep is a product that shows fast action and is an antiseptic product, which is developed in order to cater to the major and minor medical procedures. The formula of this product consists of 2% chlorhexidine gluconate, 70% isopropyl alcohol, is effective against different types of bacteria including the bacteria strain Staphylococcus aureus (MRSA), and provides continuous anti-microbial action for at least 2 days. In addition, it also offers some other products under its portfolio to cater to the different applications.
The usage and adoption in the healthcare industry to gain momentum over the forecast period.
The Healthcare industry is projected to hold a significant market share and gain momentum over the forecast period. This is majorly attributable to the fact that there is increasing prevalence and awareness among the middle-aged and older individuals in the population, which is leading to them demanding quality healthcare, and the usage of effective infection control practices to reduce the growing number of cases of HAI’s (hospital-acquired infections).